7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Atrial Remodeling D064752 1 associated lipids
Vascular Calcification D061205 1 associated lipids
Angina, Stable D060050 2 associated lipids
Bisphosphonate-Associated Osteonecrosis of the Jaw D059266 1 associated lipids
Osteoporotic Fractures D058866 1 associated lipids
Peripheral Arterial Disease D058729 7 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Peri-Implantitis D057873 1 associated lipids
Primary Myelofibrosis D055728 6 associated lipids
Chronic Periodontitis D055113 1 associated lipids
Osteophyte D054850 2 associated lipids
Hyperphosphatemia D054559 1 associated lipids
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative D054438 1 associated lipids
No-Reflow Phenomenon D054318 2 associated lipids
Acute Coronary Syndrome D054058 11 associated lipids
Hypercalciuria D053565 4 associated lipids
Renal Insufficiency, Chronic D051436 9 associated lipids
Fractures, Bone D050723 4 associated lipids
Arteriolosclerosis D050379 1 associated lipids
Atherosclerosis D050197 85 associated lipids
Dyslipidemias D050171 7 associated lipids
Hashimoto Disease D050031 1 associated lipids
Hyperparathyroidism, Primary D049950 1 associated lipids
Diabetes Complications D048909 4 associated lipids
Hypertension, Pregnancy-Induced D046110 2 associated lipids
Scleroderma, Limited D045745 1 associated lipids
Glucose Metabolism Disorders D044882 3 associated lipids
Malnutrition D044342 6 associated lipids
Irritable Bowel Syndrome D043183 8 associated lipids
Mastocytoma D034801 3 associated lipids
Hearing Loss D034381 3 associated lipids
Pulmonary Disease, Chronic Obstructive D029424 16 associated lipids
Spondylarthropathies D025242 1 associated lipids
Spondylarthritis D025241 1 associated lipids
Metabolic Syndrome D024821 44 associated lipids
Coronary Stenosis D023921 6 associated lipids
Carcinoma, Pancreatic Ductal D021441 6 associated lipids
Multiple Sclerosis, Relapsing-Remitting D020529 7 associated lipids
Multiple Sclerosis, Chronic Progressive D020528 3 associated lipids
Brain Infarction D020520 17 associated lipids
Osteoarthritis, Knee D020370 13 associated lipids
Lithiasis D020347 2 associated lipids
Ventricular Remodeling D020257 28 associated lipids
Tooth Ankylosis D020254 1 associated lipids
Venous Thrombosis D020246 11 associated lipids
Intracranial Hemorrhage, Traumatic D020198 1 associated lipids
Sleep Apnea, Obstructive D020181 9 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Hepatitis C, Chronic D019698 12 associated lipids
Hot Flashes D019584 5 associated lipids
Bone Marrow Neoplasms D019046 2 associated lipids
Myositis, Inclusion Body D018979 3 associated lipids
Sepsis D018805 11 associated lipids
Arthralgia D018771 8 associated lipids
Systemic Inflammatory Response Syndrome D018746 4 associated lipids
Breast Neoplasms, Male D018567 1 associated lipids
Bone Demineralization, Pathologic D018488 1 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Cholesteatoma, Middle Ear D018424 2 associated lipids
Foot Injuries D018409 1 associated lipids
Alphavirus Infections D018354 1 associated lipids
Hemangioma, Capillary D018324 1 associated lipids
Neoplasms, Squamous Cell D018307 1 associated lipids
Carcinoma, Neuroendocrine D018278 2 associated lipids
Carcinoma, Medullary D018276 2 associated lipids
Carcinoma, Lobular D018275 4 associated lipids
Carcinoma, Ductal, Breast D018270 19 associated lipids
Adrenocortical Adenoma D018246 1 associated lipids
Fibroma, Ossifying D018214 1 associated lipids
Giant Cell Tumor of Bone D018212 1 associated lipids
Lymphangioleiomyomatosis D018192 1 associated lipids
Bone Cysts, Aneurysmal D017824 2 associated lipids
Diabetic Foot D017719 1 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Microvascular Angina D017566 2 associated lipids
Aortic Aneurysm, Abdominal D017544 5 associated lipids
Myocardial Ischemia D017202 11 associated lipids
beta-Thalassemia D017086 5 associated lipids
Arthritis, Reactive D016918 3 associated lipids
Carotid Stenosis D016893 15 associated lipids
POEMS Syndrome D016878 1 associated lipids
Pasteurellaceae Infections D016871 2 associated lipids
Bacteroidaceae Infections D016866 2 associated lipids
Leishmaniasis, Cutaneous D016773 6 associated lipids
Diabetes, Gestational D016640 8 associated lipids
Severe Combined Immunodeficiency D016511 1 associated lipids
Peripheral Vascular Diseases D016491 8 associated lipids
Bacteremia D016470 9 associated lipids
Prosthesis-Related Infections D016459 7 associated lipids
Alveolar Bone Loss D016301 10 associated lipids
Fractures, Stress D015775 2 associated lipids
Mammary Neoplasms, Animal D015674 27 associated lipids
Osteoporosis, Postmenopausal D015663 4 associated lipids
HIV Infections D015658 20 associated lipids
Histiocytosis, Non-Langerhans-Cell D015616 4 associated lipids
Hyperostosis D015576 1 associated lipids
Arthritis, Psoriatic D015535 3 associated lipids
Leukemia, Lymphocytic, Chronic, B-Cell D015451 25 associated lipids
Weight Loss D015431 56 associated lipids
Weight Gain D015430 101 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Blázquez-Medela AM et al. Osteoprotegerin is associated with cardiovascular risk in hypertension and/or diabetes. 2012 Eur. J. Clin. Invest. pmid:22050177
Heymann MF et al. Role of the OPG/RANK/RANKL triad in calcifications of the atheromatous plaques: comparison between carotid and femoral beds. 2012 Cytokine pmid:22402034
Terpos E et al. Early effects of IL-6 receptor inhibition on bone homeostasis: a pilot study in women with rheumatoid arthritis. 2011 Nov-Dec Clin. Exp. Rheumatol. pmid:22032557
Arikan F et al. C-telopeptide pyridinoline crosslinks of type I collagen, soluble RANKL, and osteoprotegerin levels in crevicular fluid of dental implants with peri-implantitis: a case-control study. 2011 Mar-Apr Int J Oral Maxillofac Implants pmid:21483881
Crespi R et al. Corticocancellous porcine bone in the healing of human extraction sockets: combining histomorphometry with osteoblast gene expression profiles in vivo. 2011 Jul-Aug Int J Oral Maxillofac Implants pmid:21841997
Franke S et al. Advanced glycation end products affect growth and function of osteoblasts. 2011 Jul-Aug Clin. Exp. Rheumatol. pmid:21906430
Rezg R et al. Inhibitors of vascular calcification as potential therapeutic targets. 2011 Jul-Aug J. Nephrol. pmid:21688249
Reyes-García R et al. [Cardiovascular disease and bone metabolism]. 2011 Aug-Sep Endocrinol Nutr pmid:21775224
Ostrowska Z et al. Circadian concentrations of free testosterone, selected markers of bone metabolism, osteoprotegerin and its ligand sRANKL in obese postmenopausal women. 2011 Postepy Hig Med Dosw (Online) pmid:22100799
Kurabayashi M [Bone and calcium update; diagnosis and therapy of bone metabolism disease update. Calcification of atherosclerotic plaques: mechanism and clinical significance]. 2011 Clin Calcium pmid:22133823
Tsioufis C et al. Relationships of osteoprotegerin with albuminuria and asymmetric dimethylarginine in essential hypertension: integrating vascular dysfunction. 2011 Expert Opin. Ther. Targets pmid:22136618
Zhou J et al. Expression of osteoprotegerin and receptor activator of nuclear factor κB ligand in root resorption induced by heavy force in rats. 2011 J Orofac Orthop pmid:22138776
Grzibovskis M et al. Specific signaling molecule expressions in the interradicular septum in different age groups. 2011 Stomatologija pmid:22071415
Wang Y et al. Alendronate (ALN) combined with osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats. 2011 J Orthop Surg Res pmid:21752290
Plasilova M et al. Discordant gene expression signatures and related phenotypic differences in lamin A- and A/C-related Hutchinson-Gilford progeria syndrome (HGPS). 2011 PLoS ONE pmid:21738662
Ren G et al. Simultaneous administration of fluoride and selenite regulates proliferation and apoptosis in murine osteoblast-like MC3T3-E1 cells by altering osteoprotegerin. 2011 Biol Trace Elem Res pmid:21739163
Sylvester FA et al. Fecal osteoprotegerin may guide the introduction of second-line therapy in hospitalized children with ulcerative colitis. 2011 Inflamm. Bowel Dis. pmid:21744427
Weinstein RS et al. Osteoprotegerin prevents glucocorticoid-induced osteocyte apoptosis in mice. 2011 Endocrinology pmid:21771887
Lee JH et al. Tumor necrosis factor-α converting enzyme (TACE) increases RANKL expression in osteoblasts and serves as a potential biomarker of periodontitis. 2011 BMB Rep pmid:21777519
Baldi D et al. Dental implants osteogenic properties evaluated by cDNA microarrays. 2011 Implant Dent pmid:21778890
Kwan JS et al. Heritability of serum osteoprotegerin. 2011 Ann. Hum. Genet. pmid:21762114
Ibrahim T et al. Role of RANK, RANKL, OPG, and CXCR4 tissue markers in predicting bone metastases in breast cancer patients. 2011 Clin. Breast Cancer pmid:21764390
Nakashima A et al. Plasma osteoprotegerin, arterial stiffness, and mortality in normoalbuminemic Japanese hemodialysis patients. 2011 Osteoporos Int pmid:20812007
Chen WF et al. Total flavonoid fraction of the Herba epimedii extract suppresses urinary calcium excretion and improves bone properties in ovariectomised mice. 2011 Br. J. Nutr. pmid:20815976
Zinonos I et al. Anticancer efficacy of Apo2L/TRAIL is retained in the presence of high and biologically active concentrations of osteoprotegerin in vivo. 2011 J. Bone Miner. Res. pmid:20818644
Loncar G et al. Association of increased parathyroid hormone with neuroendocrine activation and endothelial dysfunction in elderly men with heart failure. 2011 J. Endocrinol. Invest. pmid:20820131
Tao H et al. P38 mitogen-activated protein kinase inhibitor, FR167653, inhibits parathyroid hormone related protein-induced osteoclastogenesis and bone resorption. 2011 PLoS ONE pmid:21886782
Lawrie A et al. Paigen diet-fed apolipoprotein E knockout mice develop severe pulmonary hypertension in an interleukin-1-dependent manner. 2011 Am. J. Pathol. pmid:21835155
Poulsen MK et al. Plasma osteoprotegerin is related to carotid and peripheral arterial disease, but not to myocardial ischemia in type 2 diabetes mellitus. 2011 Cardiovasc Diabetol pmid:21838881
Markatseli AE et al. Association of the A1330V and V667M polymorphisms of LRP5 with bone mineral density in Greek peri- and postmenopausal women. 2011 Maturitas pmid:21840657
Kauther MD et al. Calcitonin substitution in calcitonin deficiency reduces particle-induced osteolysis. 2011 BMC Musculoskelet Disord pmid:21843355
Gradosova I et al. The role of atorvastatin in bone metabolism in male albino Wistar rats. 2011 Pharmazie pmid:21901984
Straface G et al. Assessment of the genetic effects of polymorphisms in the osteoprotegerin gene, TNFRSF11B, on serum osteoprotegerin levels and carotid plaque vulnerability. 2011 Stroke pmid:21903966
Vitoratos N et al. Maternal circulating osteoprotegerin and soluble RANKL in pre-eclamptic women. 2011 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:21074311
Belibasakis GN et al. Oral biofilm challenge regulates the RANKL-OPG system in periodontal ligament and dental pulp cells. 2011 Microb. Pathog. pmid:21075196
Tripathi A et al. Bisphosphonate therapy for skeletal malignancies and metastases: impact on jaw bones and prosthodontic concerns. 2011 J Prosthodont pmid:21883630
Wattanaroonwong N et al. Oestrogen inhibits osteoclast formation induced by periodontal ligament fibroblasts. 2011 Arch. Oral Biol. pmid:21035111
D'Amelio P et al. Bone and bone marrow pro-osteoclastogenic cytokines are up-regulated in osteoporosis fragility fractures. 2011 Osteoporos Int pmid:21116815
Giner M et al. Alendronate and raloxifene affect the osteoprotegerin/RANKL system in human osteoblast primary cultures from patients with osteoporosis and osteoarthritis. 2011 Eur. J. Pharmacol. pmid:21050847
Hie M and Tsukamoto I Vitamin C-deficiency stimulates osteoclastogenesis with an increase in RANK expression. 2011 J. Nutr. Biochem. pmid:20444587
Belibasakis GN et al. Porphyromonas gingivalis induces RANKL in T-cells. 2011 Inflammation pmid:20446027
Dzida G [Decalcified bones, calcified heart?]. 2011 Kardiol Pol pmid:21678295
Yang Q et al. Plasma osteoprotegerin levels and long-term prognosis in patients with intermediate coronary artery lesions. 2011 Clin Cardiol pmid:21678453
Toffoli B et al. Osteoprotegerin promotes vascular fibrosis via a TGF-β1 autocrine loop. 2011 Atherosclerosis pmid:21679949
de Moraes M et al. Comparative immunohistochemical expression of RANK, RANKL and OPG in radicular and dentigerous cysts. 2011 Arch. Oral Biol. pmid:21683340
Ndip A et al. The RANKL/RANK/OPG signaling pathway mediates medial arterial calcification in diabetic Charcot neuroarthropathy. 2011 Diabetes pmid:21659498
Gulseren A et al. Evaluation of weekly risedronate treatment in postmenopausal women with osteoprotegerin. 2011 Panminerva Med pmid:21659972
Corallini F et al. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. 2011 J. Cell. Physiol. pmid:21660951
Costa-Rodrigues J and Fernandes MH Paracrine-mediated differentiation and activation of human haematopoietic osteoclast precursor cells by skin and gingival fibroblasts. 2011 Cell Prolif. pmid:21535267
Lee YS and Choi EM Apocynin stimulates osteoblast differentiation and inhibits bone-resorbing mediators in MC3T3-E1 cells. 2011 Cell. Immunol. pmid:21683946
Schoppet M et al. Crystallizing nanoparticles derived from vascular smooth muscle cells contain the calcification inhibitor osteoprotegerin. 2011 Biochem. Biophys. Res. Commun. pmid:21371424
Pobeha P et al. Relationship between osteoporosis and adipose tissue leptin and osteoprotegerin in patients with chronic obstructive pulmonary disease. 2011 Bone pmid:21376149
Cao H et al. Dysregulated atrial gene expression of osteoprotegerin/receptor activator of nuclear factor-κB (RANK)/RANK ligand axis in the development and progression of atrial fibrillation. 2011 Circ. J. pmid:22001292
Scialla JJ et al. Correlates of osteoprotegerin and association with aortic pulse wave velocity in patients with chronic kidney disease. 2011 Clin J Am Soc Nephrol pmid:21940840
Sfiridaki K et al. Angiogenesis-related cytokines, RANKL, and osteoprotegerin in multiple myeloma patients in relation to clinical features and response to treatment. 2011 Mediators Inflamm. pmid:21941412
Bao L et al. Anthraquinone compounds from Morinda officinalis inhibit osteoclastic bone resorption in vitro. 2011 Chem. Biol. Interact. pmid:21945525
Zhou XW et al. [Expressions of RANK, RANKL, and osteoprotegerin in male rats at different ages]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21945761
Carmona-Fernandes D et al. Soluble receptor activator of nuclear factor κB ligand/osteoprotegerin ratio is increased in systemic lupus erythematosus patients. 2011 Arthritis Res. Ther. pmid:22027240
Wang Y et al. [Interleukin-4 and osteoprotegerin suppress polyethylene wear debris-induced osteolysis in a murine air pouch model]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:22027773
Wang JZ et al. [Effect of Epimedium extract on osteoprotegerin and RANKL mRNA expressions in glucocorticoid-induced femoral head necrosis in rats]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:22027774
Ferrari-Lacraz S and Ferrari S Do RANKL inhibitors (denosumab) affect inflammation and immunity? 2011 Osteoporos Int pmid:20571772
Goto H et al. Human bone marrow adipocytes support dexamethasone-induced osteoclast differentiation and function through RANKL expression. 2011 Biomed. Res. pmid:21383509
Belibasakis GN et al. The RANKL-OPG system is differentially regulated by supragingival and subgingival biofilm supernatants. 2011 Cytokine pmid:21474331
Siomou E et al. Serum osteoprotegerin, RANKL and fibroblast growth factor-23 in children with chronic kidney disease. 2011 Pediatr. Nephrol. pmid:21479768
Sexton WM et al. Salivary biomarkers of periodontal disease in response to treatment. 2011 J. Clin. Periodontol. pmid:21480939
Cordeiro MM et al. Primary teeth show less protecting factors against root resorption. 2011 Int J Paediatr Dent pmid:21481035
Kaneuji T et al. Mechanisms involved in regulation of osteoclastic differentiation by mechanical stress-loaded osteoblasts. 2011 Biochem. Biophys. Res. Commun. pmid:21459078
Luvizuto ER et al. Raloxifene therapy inhibits osteoclastogenesis during the alveolar healing process in rats. 2011 Arch. Oral Biol. pmid:21536255
Hall J et al. A controlled clinical exploratory study on genetic markers for peri-implantitis. 2011 Eur J Oral Implantol pmid:22282733
Xu ML et al. [An update for the research progress of osteoprotegerin on coronary artery disease]. 2011 Zhonghua Xin Xue Guan Bing Za Zhi pmid:22321243
Aspenberg P et al. Targeting RANKL for reduction of bone loss around unstable implants: OPG-Fc compared to alendronate in a model for mechanically induced loosening. 2011 Bone pmid:20858557
Kurnatowska I et al. Serum osteoprotegerin is a predictor of progression of atherosclerosis and coronary calcification in hemodialysis patients. 2011 Nephron Clin Pract pmid:20861651
de Souza Faloni AP et al. Jaw and long bone marrows have a different osteoclastogenic potential. 2011 Calcif. Tissue Int. pmid:20862464
Park JS et al. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus. 2011 Eur. J. Endocrinol. pmid:20961967
Karosi T et al. Osteoprotegerin expression and sensitivity in otosclerosis with different histological activity. 2011 Eur Arch Otorhinolaryngol pmid:20963600
Tsukamoto S et al. Clinical significance of osteoprotegerin expression in human colorectal cancer. 2011 Clin. Cancer Res. pmid:21270110
Monnouchi S et al. The roles of angiotensin II in stretched periodontal ligament cells. 2011 J. Dent. Res. pmid:21270461
Chang YH et al. Serum osteoprotegerin and tumor necrosis factor related apoptosis inducing-ligand (TRAIL) are elevated in type 2 diabetic patients with albuminuria and serum osteoprotegerin is independently associated with the severity of diabetic nephropathy. 2011 Metab. Clin. Exp. pmid:21251686
Benslimane-Ahmim Z et al. Osteoprotegerin, a new actor in vasculogenesis, stimulates endothelial colony-forming cells properties. 2011 J. Thromb. Haemost. pmid:21255246
WaluÅ›-Miarka M et al. Osteoprotegerin is associated with markers of atherosclerosis and body fat mass in type 2 diabetes patients. 2011 Int. J. Cardiol. pmid:21255853
Saito CT et al. Effect of low-level laser therapy on the healing process after tooth replantation: a histomorphometrical and immunohistochemical analysis. 2011 Dent Traumatol pmid:21244626
Erkol A et al. Relation of circulating osteoprotegerin levels on admission to microvascular obstruction after primary percutaneous coronary intervention. 2011 Am. J. Cardiol. pmid:21247537
Sobue T et al. Murine TMJ loading causes increased proliferation and chondrocyte maturation. 2011 J. Dent. Res. pmid:21248355
Ribeiro FV et al. Cytokines and bone-related factors in systemically healthy patients with chronic periodontitis and patients with type 2 diabetes and chronic periodontitis. 2011 J. Periodontol. pmid:21284550
Piedra M et al. "Single nucleotide polymorphisms of the OPG/RANKL system genes in primary hyperparathyroidism and their relationship with bone mineral density". 2011 BMC Med. Genet. pmid:22185226
Kawaguchi H [Approach for therapeutic targets of osteoarthritis]. 2011 Nippon Yakurigaku Zasshi pmid:21747205
Hou WW et al. Involvement of Wnt activation in the micromechanical vibration-enhanced osteogenic response of osteoblasts. 2011 J Orthop Sci pmid:21833614
Nahidi L et al. Osteoprotegerin in pediatric Crohn's disease and the effects of exclusive enteral nutrition. 2011 Inflamm. Bowel Dis. pmid:20848544
Watkins M et al. Osteoblast connexin43 modulates skeletal architecture by regulating both arms of bone remodeling. 2011 Mol. Biol. Cell pmid:21346198
Confavreux CB Bone: from a reservoir of minerals to a regulator of energy metabolism. 2011 Kidney Int. Suppl. pmid:21346725
Caetano-Lopes J et al. Upregulation of inflammatory genes and downregulation of sclerostin gene expression are key elements in the early phase of fragility fracture healing. 2011 PLoS ONE pmid:21347301
Assmann G et al. Genetic variations in the genes encoding receptor activator nuclear factor κ B (RANK), receptor activator nuclear factor κ B ligand (RANKL) and osteoprotegerin (OPG) in patients with psoriasis and psoriatic arthritis: a case-control study. 2011 J. Dermatol. pmid:21352301
Audo R et al. Mechanisms and clinical relevance of TRAIL-triggered responses in the synovial fibroblasts of patients with rheumatoid arthritis. 2011 Arthritis Rheum. pmid:21305500
Alexander KA et al. Osteal macrophages promote in vivo intramembranous bone healing in a mouse tibial injury model. 2011 J. Bone Miner. Res. pmid:21305607
Lau CP et al. Pamidronate, farnesyl transferase, and geranylgeranyl transferase-I inhibitors affects cell proliferation, apoptosis, and OPG/RANKL mRNA expression in stromal cells of giant cell tumor of bone. 2011 J. Orthop. Res. pmid:20886653
Jabbar S et al. Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. 2011 J. Clin. Pathol. pmid:21307155
Maïmoun L et al. In peripubertal girls, artistic gymnastics improves areal bone mineral density and femoral bone geometry without affecting serum OPG/RANKL levels. 2011 Osteoporos Int pmid:21359671
Ignatius A et al. Complement C3a and C5a modulate osteoclast formation and inflammatory response of osteoblasts in synergism with IL-1β. 2011 J. Cell. Biochem. pmid:21598302
Sun CX et al. [Patterns of osteoprotegerin or nuclear factor kappa B ligand gene expression in the treatment of bone defect with bone marrow stem cell transplantation and low-frequency vibration]. 2011 Zhonghua Yi Xue Za Zhi pmid:21600122
Liu ZF et al. [Effect of ultrasound on osteoprotegerin and receptor activator nuclear factor kappaB ligand expression during root resorption in rats]. 2011 Nan Fang Yi Ke Da Xue Xue Bao pmid:21602131

Table of Content